| Title: |
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy |
| Authors: |
Cognetti, Francesco; Masetti, Riccardo; Fabi, Alessandra; Bianchi, Giulia; Santini, Donatella; Rognone, Alessia; Catania, Giovanna; Angelucci, Domenico; Naso, Giuseppe; Giuliano, Mario; Vassalli, Lucia; Vici, Patrizia; Scognamiglio, Giovanni; Generali, Daniele; Zambelli, Alberto; Colleoni, Marco; Tinterri, Corrado; Scanzi, Francesco; Vigna, Leonardo; Scavina, Paola; Gamucci, Teresa; Marrazzo, Emilia; Scinto, Angelo Fedele; Berardi, Rossana; Fabbri, Maria Agnese; Pinotti, Graziella; Franco, Daniela; Terribile, Daniela Andreina; Tonini, Giuseppe; Cianniello, Daniela; Barni, Sandro |
| Contributors: |
Cognetti, Francesco; Masetti, Riccardo; Fabi, Alessandra; Bianchi, Giulia; Santini, Donatella; Rognone, Alessia; Catania, Giovanna; Angelucci, Domenico; Naso, Giuseppe; Giuliano, Mario; Vassalli, Lucia; Vici, Patrizia; Scognamiglio, Giovanni; Generali, Daniele; Zambelli, Alberto; Colleoni, Marco; Tinterri, Corrado; Scanzi, Francesco; Vigna, Leonardo; Scavina, Paola; Gamucci, Teresa; Marrazzo, Emilia; Scinto, Angelo Fedele; Berardi, Rossana; Fabbri, Maria Agnese; Pinotti, Graziella; Franco, Daniela; Terribile, Daniela Andreina; Tonini, Giuseppe; Cianniello, Daniela; Barni, Sandro |
| Publication Year: |
2021 |
| Collection: |
Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) |
| Subject Terms: |
breast cancer; real life; early stage |
| Description: |
Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians' treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2- early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/33953182; info:eu-repo/semantics/altIdentifier/wos/WOS:000656393000001; volume:7; issue:1; firstpage:"-"; lastpage:"-"; numberofpages:8; journal:NPJ BREAST CANCER; https://hdl.handle.net/11368/2993056; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099872/ |
| DOI: |
10.1038/s41523-021-00246-4 |
| Availability: |
https://hdl.handle.net/11368/2993056; https://doi.org/10.1038/s41523-021-00246-4; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099872/ |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.75919619 |
| Database: |
BASE |